Suchergebnisse - (Subject:"PARP inhibitor")

PubPharm (290)

1

Real-world data of poly (ADP-ribose) polymerase inhibitor response in Japanese patients with ovarian cancer

enthalten in: Cancer medicine | 2024

von Uekusa, R. | Yokoi, A. | Watanabe, E. | +9

2

Successful Management of Ovarian Cancer Progressing on Olaparib by Niraparib Following Cytoreduction : A Case Report

enthalten in: In vivo (Athens, Greece) | 2024

von Endo, Y. | Kamo, N. | Kato, A. | +5

3

Interstitial lung disease caused by niraparib in ovarian cancer patient : a case report and literature review

enthalten in: Japanese journal of clinical oncology | 2024

von Shono, M. | Murakami, K. | Ohta, M. | +2

4

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit : Focus in Ovarian Cancer

enthalten in: International journal of molecular sciences | 2024

von Bailey, M. | Morand, S. | Royfman, R. | +6

5

Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer

enthalten in: Cancer | 2024

von Mutch, D. | Voulgari, A. | Chen, X. | +11

6

How BRCA and homologous recombination deficiency change therapeutic strategies in ovarian cancer : a review of literature

enthalten in: Frontiers in oncology | 2024

von Arcieri, M. | Tius, V. | Andreetta, C. | +10

7

Development of a simple high-performance liquid chromatography-ultraviolet detection method for olaparib in patients with ovarian cancer

enthalten in: Drug discoveries & therapeutics | 2024

von Yasu, T. | Nishijima, R. | Ikuta, R. | +2

8

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer : a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

enthalten in: Frontiers in pharmacology | 2024

von Wei, Y. | He, L. | Liu, T. | +6

9

Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials

in: Frontiers in Pharmacology | 2024

von Yan Wei | Li He | Tao Liu | +6

10

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer

in: International Journal of Molecular Sciences | 2024

von Morgan Bailey | Susan Morand | Rachel Royfman | +6

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[29]